Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study | Zendy

Aoife G. Cotter | Zendy; S.M.E. Vrouenraets | Zendy; Jennifer J. Brady | Zendy; Ferdinand W.N.M. Wit | Zendy; Christoph A. Fux | Zendy; Hansjakob Furrer | Zendy; Kees Brinkman | Zendy; Caroline Sabin | Zendy; Peter Reiss | Zendy; Patrick Mallon | Zendy

Open Access

Impact of Switching From Zidovudine to Tenofovir Disoproxil Fumarate on Bone Mineral Density and Markers of Bone Metabolism in Virologically Suppressed HIV-1 Infected Patients; A Substudy of the PREPARE Study

Author(s) -

Aoife G. Cotter,

S.M.E. Vrouenraets,

Jennifer J. Brady,

Ferdinand W.N.M. Wit,

Christoph A. Fux,

Hansjakob Furrer,

Kees Brinkman,

Caroline Sabin,

Peter Reiss,

Patrick Mallon

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2012-3686

Subject(s) - bone mineral , medicine , n terminal telopeptide , zidovudine , bone remodeling , emtricitabine , lamivudine , tenofovir , osteocalcin , endocrinology , urology , bone density , gastroenterology , human immunodeficiency virus (hiv) , viral load , osteoporosis , antiretroviral therapy , immunology , chemistry , virus , hepatitis b virus , biochemistry , alkaline phosphatase , viral disease , enzyme

In virologically suppressed, antiretroviral-treated patients, the effect of switching to tenofovir (TDF) on bone biomarkers compared to patients remaining on stable antiretroviral therapy is unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research